glp-1 agonists and pancreatitis Enzyme Rise May Link GLP-1, Clinical Focus on GLP-1 Agonists
Description
These GLP-1 receptor agonists can be categorized as either short-acting compounds, which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compounds (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose
(Lausanne) 12 , 665537 (2021)
A tri-agonist developed by the same company targeting GIP-1R/GIPR/GCGR, retatrutide, demonstrated better weight loss effects in Phase 3 compared to tirzepatide
the Stockholm CREAtinine Measurements (SCREAM) project
On a broader societal level, the use of GLP-1 medications for weight loss may be reinforcing the negative stigmas around fatness and being overweight that often contribute to the development of eating disorders
Bickel is a behavioral health research professor with the Fralin Biomedical Research Institute at Virginia Tech in Roanoke
